HELIXATE Side Effects

6773666-9 | Atrial Fibrillation, Dizziness, Dry Throat, Flushing, Headache, Hyperhidrosis, Malaise, Tachycardia
on Jun 08, 2010 Male patient from UNITED KINGDOM , 63 years of age, weighting 308.6 lb, was diagnosed with factor viii deficiency and was treated with Helixate (View Usage). Patient experienced the following unwanted or unexpected effects: atrial fibrillation (What is atrial fibrillation?), dizziness (What is dizziness?), dry throat, flushing, headache (What is headache?), hyperhidrosis, malaise, tachycardia. Helixate dosage: . During the same period patient was treated with ATORVASTATIN (View Atorvastatin Review and Atorvastatin Label ), BETAMETHASONE (View Betamethasone Review and Betamethasone Label ), LACIDIPINE (View Lacidipine Review and Lacidipine Label ), METFORMIN (View Metformin Review and Metformin Label ), RAMIPRIL (View Ramipril Review and Ramipril Label ).

6759763-2 |
Patient was taking Helixate (View Usage). on Jun 02, 2010 from UNITED STATES Additional patient health information: Male patient , 51 years of age, . Helixate dosage: .

6474085-5 | Anti Factor Viii Antibody Positive, Haemorrhage
Adverse event was reported on Nov 19, 2009 by a Male patient taking Helixate (View Usage) (Dosage: ) was diagnosed with factor viii deficiency and. Location: GERMANY , child 2 years of age, weighting 30.86 lb, After Helixate was administered, patient had the following side effects: anti factor viii antibody positive, haemorrhage. Patient was hospitalized.

6462165-X | Duodenal Ulcer Haemorrhage, Factor Viii Inhibition, Haemarthrosis, Urticaria
on Oct 28, 2009 Male patient from ITALY , 70 years of age, was diagnosed with factor viii deficiency, haemarthrosis and was treated with Helixate (View Usage). Patient experienced the following unwanted or unexpected effects: duodenal ulcer haemorrhage, factor viii inhibition, haemarthrosis, urticaria. Helixate dosage: . During the same period patient was treated with NOVOSEVEN (Total Daily Dose: 540 ?g/kg) (View Novoseven Review and Novoseven Label ).


6447840-5 | Angina Unstable, Coronary Artery Disease, Coronary Artery Occlusion, Duodenal Ulcer Haemorrhage, Factor Viii Inhibition, Haemarthrosis, Hypersensitivity, Hypotension, Infusion Related Reaction
on Oct 28, 2009 Male patient from ITALY , 70 years of age, was diagnosed with factor viii deficiency, haemarthrosis and was treated with Helixate (View Usage). Patient had the following side effects: angina unstable, coronary artery disease (What is coronary artery disease?), coronary artery occlusion, duodenal ulcer haemorrhage, factor viii inhibition, haemarthrosis, hypersensitivity, hypotension, infusion related reaction. Helixate dosage: . During the same period patient was treated with NOVOSEVEN (Total Daily Dose: 540 ?g/kg) (View Novoseven Review and Novoseven Label ).

5592752-2 | Factor Viii Inhibition, Injection Site Extravasation
Patient was taking Helixate (View Usage). After Helixate was administered, patient had the following side effects: factor viii inhibition, injection site extravasation on Jan 11, 2008 from FRANCE Additional patient health information: Male patient , child 2 years of age, was diagnosed with factor viii deficiency and. Helixate dosage: .

5483268-2 | Factor Viii Inhibition
Adverse event was reported on Sep 09, 2007 by a Male patient taking Helixate (View Usage) (Dosage: ) was diagnosed with factor viii deficiency and. Location: FRANCE , child 2 years of age, Patient experienced the following unwanted or unexpected effects: factor viii inhibition.

5449833-3 | Factor Viii Inhibition
on Aug 22, 2007 Male patient from FRANCE , 30 years of age, was diagnosed with factor viii deficiency and was treated with Helixate (View Usage). Patient had the following side effects: factor viii inhibition. Helixate dosage: .

5443198-9 | Factor Viii Inhibition
on Aug 14, 2007 Male patient from FRANCE , 30 years of age, was diagnosed with factor viii deficiency and was treated with Helixate (View Usage). After Helixate was administered, patient had the following side effects: factor viii inhibition. Helixate dosage: .

5443188-6 | Anti Factor Viii Antibody Positive
Patient was taking Helixate (View Usage). Patient experienced the following unwanted or unexpected effects: anti factor viii antibody positive on Aug 14, 2007 from FRANCE Additional patient health information: Male patient , 30 years of age, was diagnosed with factor viii deficiency and. Helixate dosage: .

5378290-0 | Factor Viii Inhibition, Haemorrhage
Adverse event was reported on Mar 21, 2007 by a Male patient taking Helixate (View Usage) (Dosage: ) was diagnosed with factor viii deficiency and. Location: UNITED KINGDOM , 36 years of age, Patient had the following side effects: factor viii inhibition, haemorrhage. During the same period patient was treated with MONOCLATE P (View Monoclate-p Review and Monoclate-p Label ), MONARC M (View Monarc-m Review and Monarc-m Label ).

5369835-5 | Factor Viii Inhibition
on May 21, 2007 Male patient from UNITED KINGDOM , 27 years of age, weighting 176.1 lb, was diagnosed with factor viii deficiency and was treated with Helixate (View Usage). After Helixate was administered, patient had the following side effects: factor viii inhibition. Helixate dosage: 8000 Iu, Total Daily.

5368473-8 | Factor Viii Inhibition, Haemorrhage
on Mar 21, 2007 Male patient from UNITED KINGDOM , 36 years of age, was diagnosed with factor viii deficiency and was treated with Helixate (View Usage). Patient experienced the following unwanted or unexpected effects: factor viii inhibition, haemorrhage. Helixate dosage: . During the same period patient was treated with MONOCLATE P (View Monoclate-p Review and Monoclate-p Label ), MONARC M (View Monarc-m Review and Monarc-m Label ).

5151928-9 | Factor Viii Inhibition
Patient was taking Helixate (View Usage). Patient had the following side effects: factor viii inhibition on Oct 23, 2006 from FRANCE Additional patient health information: Male patient , weighting 26.46 lb, was diagnosed with factor viii deficiency, haemorrhage and. Helixate dosage: Qd Intravenous. Patient was hospitalized.

5118485-4 | Factor Viii Inhibition
Adverse event was reported on Sep 14, 2006 by a Male patient taking Helixate (View Usage) (Dosage: See Image) was diagnosed with factor viii deficiency, haemorrhage, haemorrhage prophylaxis and. Location: FRANCE , weighting 26.46 lb, After Helixate was administered, patient had the following side effects: factor viii inhibition. Patient was hospitalized.

5110809-7 | Anti Factor Viii Antibody Positive
on Aug 30, 2006 Male patient from FRANCE , weighting 26.46 lb, was diagnosed with factor viii deficiency, haemorrhage, haemorrhage prophylaxis and was treated with Helixate (View Usage). Patient experienced the following unwanted or unexpected effects: anti factor viii antibody positive. Helixate dosage: See Image. Patient was hospitalized.

5107919-7 | Central Venous Catheterisation, Factor Viii Inhibition
on Aug 30, 2006 Male patient from FRANCE , weighting 26.46 lb, was diagnosed with factor viii deficiency, haemorrhage, haemorrhage prophylaxis and was treated with Helixate (View Usage). Patient had the following side effects: central venous catheterisation, factor viii inhibition. Helixate dosage: Ni, Qd, Intravenous (see Image). Patient was hospitalized.

5092857-9 | Acute Respiratory Distress Syndrome, Dyspnoea, Hypoxia, Leukocytosis, Lung Disorder, Monocytosis, Pneumonia, Pyrexia
Patient was taking Helixate (View Usage). After Helixate was administered, patient had the following side effects: acute respiratory distress syndrome, dyspnoea, hypoxia, leukocytosis, lung disorder, monocytosis, pneumonia (What is pneumonia?), pyrexia on Oct 07, 2004 from FRANCE Additional patient health information: Male patient , 57 years of age, was diagnosed with factor viii deficiency and. Helixate dosage: Intravenous. During the same period patient was treated with RED BLOOD CELL CONCENTRATES (RED BLOOD CELLS, CONCENTRATED) (View Red Blood Cell Concentrates (red Blood Cells, Concentrated) Review and Red Blood Cell Concentrates (red Blood Cells, Concentrated) Label ), SUFENTA (View Sufenta Review and Sufenta Label ), DIPRIVAN (View Diprivan Review and Diprivan Label ), TRACRIUM (View Tracrium Review and Tracrium Label ), EPHEDRINE (View Ephedrine Review and Ephedrine Label ), KETAMINE HCL (View Ketamine Hcl Review and Ketamine Hcl Label ). Patient was hospitalized.

5090695-4 | Acute Respiratory Distress Syndrome, Hypoxia, Interstitial Lung Disease, Leukocytosis, Monocytosis, Pneumonia
Adverse event was reported on Oct 07, 2004 by a Male patient taking Helixate (View Usage) (Dosage: Intravenous) was diagnosed with factor viii deficiency and. Location: FRANCE , 57 years of age, Patient experienced the following unwanted or unexpected effects: acute respiratory distress syndrome, hypoxia, interstitial lung disease, leukocytosis, monocytosis, pneumonia (What is pneumonia?). During the same period patient was treated with RED BLOOD CELL CONCENTRATES (RED BLOOD CELLS, CONCENTRATED) (View Red Blood Cell Concentrates (red Blood Cells, Concentrated) Review and Red Blood Cell Concentrates (red Blood Cells, Concentrated) Label ), SUFENTA (View Sufenta Review and Sufenta Label ), DIPRIVAN (View Diprivan Review and Diprivan Label ), TRACRIUM (View Tracrium Review and Tracrium Label ), EPHEDRINE (View Ephedrine Review and Ephedrine Label ), KETAMINE HCL (View Ketamine Hcl Review and Ketamine Hcl Label ). Patient was hospitalized.